Comparing BioLife Solutions (BLFS) & Shire (SHPG)

BioLife Solutions (NASDAQ: BLFS) and Shire (NASDAQ:SHPG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for BioLife Solutions and Shire, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions 0 0 2 0 3.00
Shire 0 6 8 0 2.57

BioLife Solutions currently has a consensus price target of $6.50, indicating a potential upside of 2.52%. Shire has a consensus price target of $212.18, indicating a potential upside of 35.61%. Given Shire’s higher probable upside, analysts plainly believe Shire is more favorable than BioLife Solutions.


This table compares BioLife Solutions and Shire’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLife Solutions -52.10% -49.92% -29.47%
Shire 10.95% 14.41% 6.60%


Shire pays an annual dividend of $0.92 per share and has a dividend yield of 0.6%. BioLife Solutions does not pay a dividend. Shire pays out 17.3% of its earnings in the form of a dividend.

Valuation and Earnings

This table compares BioLife Solutions and Shire’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLife Solutions $8.23 million 10.50 -$6.87 million ($0.42) -15.10
Shire $11.40 billion 4.13 $327.40 million $5.31 29.47

Shire has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Shire, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

9.4% of BioLife Solutions shares are owned by institutional investors. Comparatively, 20.2% of Shire shares are owned by institutional investors. 36.8% of BioLife Solutions shares are owned by insiders. Comparatively, 2.0% of Shire shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

BioLife Solutions has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Shire has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.


Shire beats BioLife Solutions on 12 of the 16 factors compared between the two stocks.

BioLife Solutions Company Profile

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with's FREE daily email newsletter.

Leave a Reply